1.
Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway
by Zhong, Zhenyu
Cancer letters, 2017, Vol.403, p.305-317
2.
Vascular endothelial growth factors (VEGFs) and stroke
by Greenberg, David A
Cellular and molecular life sciences : CMLS, 2013, Vol.70 (10), p.1753-1761
3.
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth
by Dridi, Sami
Nature medicine, 2009, Vol.15 (9), p.1023-1030
4.
Regulation of Vascular Endothelial Growth Factor Signaling by miR-200b
by Choi, Y.C., Kyung Hee University, Yongin, Republic of Korea
Molecules and Cells, 32(1), pp.77-82
5.
VEGF Signaling through Neuropilin 1 Guides Commissural Axon Crossing at the Optic Chiasm
by Erskine, Lynda
Neuron (Cambridge, Mass.), 2011, Vol.70 (5), p.951-965
6.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Functions to Promote Uterine Decidual Angiogenesis during Early Pregnancy in the Mouse
by Douglas, Nataki C
Endocrinology (Philadelphia), 2009, Vol.150 (8), p.3845-3854
7.
Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity
by Palmer, Kirsten R
Hypertension (Dallas, Tex. 1979), 2015, Vol.66 (6), p.1251-1259
8.
Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction
by Zangi, Lior
Nature biotechnology, 2013, Vol.31 (10), p.898-907
9.
VEGFR1-activity-independent metastasis formation
by Dawson, Michelle R
Nature (London), 2009, Vol.461 (7262), p.E4-E4
10.
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
by Avery, Robert L
British journal of ophthalmology, 2014, Vol.98 (12), p.1636-1641
11.
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma
by Liu, Yanqiu
Nature medicine, 2008, Vol.14 (11), p.1236-1246
12.
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
by Shojaei, Farbod
Cancer letters, 2012, Vol.320 (2), p.130-137
13.
Vascular endothelial growth factor signaling in acute myeloid leukemia
by Kampen, Kim R
Cellular and molecular life sciences : CMLS, 2013, Vol.70 (8), p.1307-1317
14.
Human cardiovascular progenitor cells develop from a KDR + embryonic-stem-cell-derived population
by Keller, Gordon M
Nature (London), 2008, Vol.453 (7194), p.524-528
15.
Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism
by Machnik, A
Nature medicine, 2009, Vol.15 (5), p.545-552
16.
Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling
by Chen, Huanjun
Cancer letters, 2016, Vol.382 (1), p.44-52
17.
VEGF and the diabetic kidney: more than too much of a good thing
by Majumder, Syamantak
Journal of diabetes and its complications, 2016, Vol.31 (1), p.273-279
18.
Adverse effects of anticancer agents that target the VEGF pathway
by Chen, Helen X
Nature reviews. Clinical oncology, 2009, Vol.6 (8), p.465-477
19.
FOXF2 deficiency permits basal-like breast cancer cells to form lymphangiogenic mimicry by enhancing the response of VEGF-C/VEGFR3 signaling pathway
by Wang, Qing-Shan
Cancer letters, 2018, Vol.420, p.116-126
20.
A mechanosensitive transcriptional mechanism that controls angiogenesis
by Mammoto, Tadanori
Nature, 2009, Vol.457 (7233), p.1103-1108
